Eledon Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
ELDN Eledon Pharmaceuticals Inc
NTCT Netscout Systems Inc
CIO City Office REIT Inc
HMHC Houghton Mifflin Harcourt Co
PBA Pembina Pipeline Corp
ZTS Zoetis Inc
HMPT Home Point Capital Inc
KWR Quaker Chemical Corp
TWO Two Harbors Investment Corp
BV Brightview Holdings Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Eledon Pharmaceuticals, Inc., formerly Novus Therapeutics, Inc., is a pharmaceutical company. The Company is focused on developing targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases. The Company’s lead product candidate, AT-1501, is a humanized monoclonal antibody (mAb), designed to target CD40 Ligand (CD40L), a molecule expressed on the surface of human immune system T cells. The central role of CD40/CD40L signaling in generating pro-inflammatory responses makes it an attractive candidate for therapeutic intervention in autoimmune disease, induction and maintenance of transplant tolerance, and neuroinflammation. Blocking the activation of the CD40L pathway ameliorates disease progression and pathology in preclinical models of autoimmunity and prevents acute and long-term allograft transplant rejection in multiple animal species.

The symbol you entered, NVUS, changed to ELDN.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:
  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    4:00p ET 05/06/21
  • Last (size)
  • 52-Wk Range
    6.16 - 27.32
  • (09/04/20 - 10/30/20)
  • 159.5%
  • Market Cap
  • Shares Outstanding
  • -18.90
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.8
  • 40.45
  • (% of float 04/15/21)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.